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Background
The purpose of this study was to produce peptide-and-
lipid-induced murine monoclonal antibodies (mAbs)
that replicate the characteristics of the 2F5 and/or 4E10
human antibodies for binding both to the membrane
proximal external region (MPER) of gp41 and the adja-
cent lipid bilayer for neutralizing HIV-1 infection of CD4+
lymphocytes.
Methods
Liposomes containing both a synthetic MPER peptide
(662-LELDKWASLWNWFDITNWLWYIK-684) as a pep-
tide antigen, phosphatidylinositol-4-phosphate (PIP) as a
lipid antigen, and monophosphoryl lipid A as a potent
adjuvant were used as a formulation to immunize mice.
MAbs were then produced and tested for binding to
MPER, gp41, and PIP and for the ability to neutralize a
replication-competent molecular clone of HIV-1 encod-
ing a primary envelope protein and Renilla luciferase as
reporter in human peripheral blood mononuclear cells
(PBMC).
Results
Multispecific IgM MAbs were produced that bound PIP
and that simultaneously bound to either the core MPER
site of 2F5 or that overlapped with the 4E10 site. The
mAbs also bound to negatively charged phospholipids,
including cardiolipin, and lipid A. They had lipid binding
specificities similar to those observed for 4E10 (Matyas et
al., BBA, 2009; 1788: 660–5). In contrast to 4E10, these
murine mAbs bound weakly to cholesterol and not to
galactosyl ceramide. While these murine mAbs neutral-
ized HIV-1 less well than 2F5 IgG, they inhibited more
efficiently than the IgM isotype of 2F5.
Conclusion
This study employed widely used, clinically acceptable,
safe, generic antigen-adjuvant constituents that poten-
tially could be used for human immunization. Using lipo-
somes containing MPER peptide and PIP as antigens and
lipid A as an adjuvant for immunization, multispecific
antibodies that simultaneously bind gp41 MPER and
adjacent lipid and neutralize HIV-1 infection in a PBMC
assay were induced. This is the first time that both the pep-
tide and lipid binding specificities of 2F5 (or 4E10) have
been induced experimentally in a neutralizing antibody.
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